Kala Pharmaceuticals Garners $68,000,000 Series C Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e947e707-9ea3-401a-a2c6-dd9abf1602f8 - Date
4/14/2016 - Company Name
Kala Pharmaceuticals - Mailing Address
100 Beaver St. Waltham, MA 02453 USA - Company Description
Kala Pharmaceuticals, Inc. is a biotechnology company founded upon a proprietary drug delivery technology. By utilizing this unique technology, Kala aims to address unmet therapeutic needs of various diseases and conditions in a fundamentally novel way. - Website
http://www.kalarx.com - Transaction Type
Venture Equity - Transaction Amount
$68,000,000 - Transaction Round
Series C - Proceeds Purposes
The proceeds of the financing will be used to advance the confirmatory Phase 3 trial for KPI – 121 for the treatment of inflammation and pain following cataract surgery, two parallel P hase 3 studies for KPI – 121 in dry eye disease, and for general corporate purposes. - M&A Terms
- Venture Investor
Longitude Capital Management - Venture Investor
OrbiMed - Venture Investor
Vivo Capital - Venture Investor
RA Capital - Venture Investor
Polaris Partners - Venture Investor
Lux Capital - Venture Investor
CVF
